# A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Study · id `cardio:ct-nct01729871` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01729871](<https://clinicaltrials.gov/study/NCT01729871>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01729871

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

## Technical summary

Registry record NCT01729871. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-10 (actual). Results posted on 2015-11-10.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 253 participants (enrolled count; ClinicalTrials.gov record NCT01729871, source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)
- Start date: 2013-02 (registry gives no type) (ClinicalTrials.gov record NCT01729871, source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01729871, source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01729871, source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)
- Results first posted: 2015-11-10 (ClinicalTrials.gov record NCT01729871, source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)
- Countries: United States; Belgium; France; Germany; United Kingdom (ClinicalTrials.gov record NCT01729871, source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01729871-2017-03-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
- Acronym: VENTURE-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): rivaroxaban
- Intervention (Drug): uninterrupted vitamin K antagonist (VKA)
- Lead sponsor: Janssen Scientific Affairs, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Janssen Scientific Affairs, LLC (`cardio:org-janssen-scientific-affairs-llc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation (`cardio:pubmed-25975659`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d9ebad36282b7cc6d6e98cc84a49f833772b1f122f30b1736aa42021a4ddab72
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
